Skip to content

Study · Randomized controlled trial · n = 40 · 2010

5 results

A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers.

Ruff D, Crockford D, Girardi G, Zhang Y

Annals of the New York Academy of Sciences1 Apr 2010Cited by 41 (Europe PMC)

PMID20536472 (opens in a new tab)DOI10.1111/j.1749-6632.2010.05474.x (opens in a new tab)PepBankPUB-20536472
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In healthy volunteers, adverse events with intravenous Tbeta4 were infrequent and mild or moderate in intensity.

    In plain wordsIn healthy volunteers, side effects of intravenous thymosin beta‑4 were infrequent and mild or moderate.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableTreatment-emergent adverse events
    Study

    n = 40

    Outcome group
    Adverse events · Whole body
    Studied dose
    42, 140, 420 or 1260 mg · intravenous · single dose and 14 days dailyAs given in this study (human).

    Source sentences

    Summary
    Adverse events were infrequent, and mild or moderate in intensity.
    2 context sentences
    Summary · context
    Four cohorts, with 10 healthy subjects each, were given a single intravenous dose of placebo or synthetic Tbeta4.
    Summary · context
    Cohorts received ascending doses of either 42, 140, 420, or 1260 mg.
  2. 02HumanRandomized controlled trialSafety outcome

    In healthy volunteers, intravenous Tbeta4 caused no dose limiting toxicities or serious adverse events.

    In plain wordsIn healthy volunteers, intravenous thymosin beta‑4 caused no dose limiting toxicity and no serious side effects.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeDose limiting toxicities and serious adverse events
    Study

    n = 40

    Outcome group
    Adverse events · Whole body
    Studied dose
    42, 140, 420 or 1260 mg · intravenous · single dose and 14 days dailyAs given in this study (human).

    Source sentences

    Summary
    There were no dose limiting toxicities or serious adverse events.
    2 context sentences
    Summary · context
    Four cohorts, with 10 healthy subjects each, were given a single intravenous dose of placebo or synthetic Tbeta4.
    Summary · context
    Cohorts received ascending doses of either 42, 140, 420, or 1260 mg.
  3. 03HumanRandomized controlled trialPharmacokinetics

    In healthy volunteers, the single-dose pharmacokinetic profile of intravenous Tbeta4 showed a dose proportional response.

    In plain wordsIn healthy volunteers, blood levels of a single intravenous thymosin beta‑4 dose rose in proportion to the dose.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableDose proportionality of single-dose pharmacokinetics
    Study

    n = 40

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    42, 140, 420 or 1260 mg · intravenous · single doseAs given in this study (human).

    Source sentences

    Summary
    Pharmacokinetic profile for single dose showed a dose proportional response
    2 context sentences
    Summary · context
    Four cohorts, with 10 healthy subjects each, were given a single intravenous dose of placebo or synthetic Tbeta4.
    Summary · context
    Cohorts received ascending doses of either 42, 140, 420, or 1260 mg.
  4. 04HumanRandomized controlled trialPharmacokinetics

    In healthy volunteers, the half-life of intravenous Tbeta4 increased with increasing single dose.

    In plain wordsIn healthy volunteers, the half-life of intravenous thymosin beta‑4 became longer as the dose increased.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseHalf-life after single dose
    Study

    n = 40

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    42, 140, 420 or 1260 mg · intravenous · single doseAs given in this study (human).

    Source sentences

    Summary
    an increasing half-life with increasing dose.
    2 context sentences
    Summary · context
    Four cohorts, with 10 healthy subjects each, were given a single intravenous dose of placebo or synthetic Tbeta4.
    Summary · context
    Cohorts received ascending doses of either 42, 140, 420, or 1260 mg.
  5. 05HumanRandomized controlled trialSafety outcome

    In healthy volunteers, single or 14-day daily intravenous Tbeta4 over 42-1260 mg was well tolerated with no evidence of dose limiting toxicity.

    In plain wordsIn healthy volunteers, intravenous thymosin beta‑4 for one dose or 14 days was well tolerated.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeTolerability over the 42-1260 mg dose range
    Study

    n = 40

    Outcome group
    Adverse events · Whole body
    Studied dose
    42, 140, 420 or 1260 mg · intravenous · single dose or 14 days dailyAs given in this study (human).

    Source sentences

    Summary
    Synthetic Tbeta4 given intravenously as a single dose or in multiple daily doses for 14 days over a dose range of 42-1260 mg was well tolerated with no evidence of dose limiting toxicity.
    2 context sentences
    Summary · context
    Four cohorts, with 10 healthy subjects each, were given a single intravenous dose of placebo or synthetic Tbeta4.
    Summary · context
    Cohorts received ascending doses of either 42, 140, 420, or 1260 mg.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.